Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Phase 3

Completed

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT00494884
• Lead Sponsor: Novartis

Brief Summary

This study will investigate efficacy and safety of vildagliptin in patients with low baseline levels starting at an HbA1C level of 6.5% to support convenient early intervention with combination therapies. In parallel, morning and evening dosing will be evaluated in this patient population for the first time.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06
• Study First Submitted: 2007-06-29
• Study First Submitted QC: 2007-06-29
• Study First Posted: 2007-07-02
• Primary Completion: 2008-07
• Study Completion: 2008-07
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-23
• Last Update Posted: 2017-02-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Male, non-fertile female or female of childbearing potential using a medically approved birth control method
• Patients who have received metformin for at least three months prior to visit 1 and have been on a stable dose for a minimum of 8 weeks prior to visit 1
• Agreement to maintain the same dose of metformin throughout the study
• Age in the range of 18-85 years inclusive.
• HbA1c in the range of 6.5 - 8.0% (inclusive) at visit 1
• Agreement to maintain prior diet and exercise habits during the full course of the study
• Ability to comply with all study requirements and signed informed consent to participate in the study.

Exclusion Criteria

• Pregnant or lactating female

A history of:

• type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushing's syndrome and acromegaly.
• acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months.

Any of the following significant laboratory abnormalities:

• ALT, AST greater than 2 times the upper limit of the normal range at visit 1.
• Direct bilirubin greater than the upper limit of the normal range at visit 1.
• Serum creatinine levels equal to or greater than 1.5 mg/dL (132 umol/L) males, equal to or greater than 1.4 mg/dL (123 umol/L) females, or a history of abnormal creatinine clearance at visit 1.
• Clinically significant TSH values outside of normal range at visit 1.
• Clinically significant laboratory abnormalities, confirmed by repeat measurement, other than hyperglycemia, hyperinsulinemia, and glycosuria at visit 1 Treatment with any oral anti-diabetic other than metformin within 3 months prior to visit 1

Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change from baseline in HbA1c	24 weeks

Secondary Outcome Measures

Name	Time	Method
Responder rates	24 weeks
Change in systolic and diastolic blood pressure	24 weeks
Change from baseline in fasting plasma glucose	24 weeks
Adverse event profiles including gastrointestinal tolerability and hypoglycemia	24 weeks
Change from baseline in insulin and proinsulin in a subgroup of patients	24 weeks

Trial Locations

Locations (1)

Novartis Investigative Site; 🇩🇪 Bochum, Germany